The Latest Cardiac and Vascular News
New health tech company to compete with consumer tech giants Apple and Fitbit IRVINE, Calif., May 17, 2021 /PRNewswire/ — CardieX Limited (ASX: CDX), a global health technology company focused on hypertension, cardiovascular disease, and vascular health disorders, today announced CONNEQT™, a new consumer health company that will focus on home vital signs monitors, […]
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. “We continue to work closely with our existing clinical trial sites, […]
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern […]
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to two years 88% of the treated patients had isolated systolic hypertension (ISH) 70.6% of all treated patients and 80% of treated ISH patients had their blood pressure under control at 24 months NEW HOPE, Pa., […]
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship […]
— Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO — — Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor – ANN ARBOR, […]
Phase 1 healthy volunteer study demonstrates that oral administration of IMB-101 is well tolerated and exhibits predictable pharmacokinetic characteristics Pre-clinical study showed that IMB-101 improves cardiac contractile function and fibrosis post-myocardial infarction, highlighting its therapeutic potential in the context of myocardial ischemia and heart failure BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical […]
AT-01 detected cardiac amyloid in AL and ATTR patients with known cardiac disease with 95% sensitivity AT-01 detected cardiac amyloid in patients with AL or ATTR amyloid with normal levels of serum NT-proBNP AT-01 has the potential to distinguish AL and ATTR amyloidosis based on organ distribution SOUTH SAN FRANCISCO, […]
Mavacamten, a potential first-in-class cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), showed improvement in health status compared to placebo at 30 weeks in EXPLORER-HCM trial Findings of new analysis published simultaneously in The Lancet PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data […]
Minimally-invasive, implant-free technology for heart failure patients studied at 1 and 3 months AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved […]
